Lophora ApS
Lophora is a clinical-stage CNS therapeutics company developing differentiated, next-generation neuroactive medicines designed to induce neuroplasticity and address significant unmet needs in neuropsychiatry.
Lophora has identified and patented a new class of proprietary ligands. The company’s lead compound, LPH-5, is a highly selective small-molecule agonist of the serotonin 5-HT2A receptor with robust CNS exposure and demonstrated target engagement. In preclinical models, LPH-5 has shown activity at sub-perceptual (non-psychedelic) dose levels. LPH-5 has completed dosing in a Phase I clinical trial, with early read-outs indicating a favourable safety and tolerability profile, supporting its potential suitability for multiple-dosing paradigms.
After being spun out from University of Copenhagen and the first investment from the Novo Nordisk Foundation, the company has received funding from Innovation Fund Denmark and a syndicate of family offices and private individuals.